Monday U.S. Featured Earnings Avid Bioservices, Inc. (NASDAQ: CDMO) (Q4) EPS of two ...
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.
The specialty healthcare services provider had a fiscal fourth quarter to forget.
The CDMO released fourth-quarter and fiscal 2023 earnings.
September S&P 500 futures (ESU23) are down -0.19%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.29% this morning after three major U.S. benchmark indices ended the regular session lower...
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,
The bio-manufacturer's ongoing expansion efforts are a hit with investors.
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 275% and 5.61%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?